GSK : to present updates on its industry-leading infectious disease portfolio at IDWeek 2022

First presentation of RSV Older Adult vaccine candidate's pivotal phase III efficacy and safety data




New data showing Shingrix... | October 12, 2022

Related Keywords

Washington ,District Of Columbia ,United States ,Geneva ,Genè ,Switzerland ,Glasgow ,Glasgow City ,United Kingdom ,Canada ,American ,British ,Tinof Schwarz ,Anne Strezova ,Marial Agostini ,Tony Wood ,Keiths Kaye ,Jennifer Han ,Rodrigoe Mendes ,Ashishv Joshi ,Jill Walker ,Vocabria Rekambys ,Shionogi Co Ltd ,World Health Organization ,A National ,Fair Health ,Infectious Disease Society Of America Idweek ,Company Annual Report On Form ,Analysis Of Co ,Eu Health Care Settings ,Pfizer Inc ,Global Health ,Clinical Program ,Infectious Disease Society ,Viiv Healthcare ,Chief Scientific Officer ,Respiratory Syncytial Virus ,Prefusionf Protein Candidate Vaccine ,Candidate Respiratory Syncytial Virus ,Prefustionf Protein Investigational Vaccine ,Investigational Respiratory Syncytial Virus ,Prefusionf Protein Vaccine ,Interim Analysis ,Protection Against Herpes Zoster ,Adjuvanted Recombinant Zoster Vaccine ,Interim Efficacy ,Safety Results ,Initial Vaccination ,World Effectiveness ,Early Treatment ,Viral Pharmacodynamics ,Igg Monoclonal Antibody Sotrovimab Administered ,Intramuscular Injection ,Early Mild To Moderated ,Resistance Analysis ,Sotrovimab Treatment ,Participants With Mild To Moderate ,Intravenous Sotrovimab ,Co Resistance Among Escherichia ,Urine Isolates ,Female Outpatients ,Co Resistance Among Klebsiella ,Regional Distribution ,Antimicrobial Resistance Among Female Outpatients ,Urine Klebsiella ,Multicenter Evaluation ,Treatment Success ,Uncomplicated Urinary Tract Infection ,Isolates Resistant ,Commonly Used Oral Therapies ,Gepotidacin Against Escherichia ,Literature Review ,Real World Experience ,Drug Regimen Dolutegravir ,Would Not Have Met Inclusion Criteria ,Virologically Suppressed ,Including Those Aged ,Pooled Results ,Drug Regimen ,Drug Regimens ,Based Regimens ,Older People Living ,Veterans Aging Cohort Study ,World Treatment Experience ,Treatment Naive People ,Initiated Treatment ,Single Tablet ,Treat Setting ,Those Naive ,Baseline Viral Loads ,Real World Observational Study ,Infected Patients Who Switched ,Reverse Transcriptase Inhibitors ,British Columbia ,Effectiveness Study ,Cabotegravir Plus Rilpivirine Long Acting ,Care Settings ,Key Clinical ,Implementation Outcomes ,Implementation Arm ,Long Acting Cabotegravir ,Safety Outcomes Through Week ,First Year ,Provider Perspectives ,Rilpivirine Long Acting ,Observational Real World Study ,Cisgender Women ,National Survey ,Preferences Among ,Hispanic Men ,Patient Preferences ,Starting Daily ,Long Acting Injectable ,Prophylaxis Among ,Who Have Sex ,Heavily Treatment Experienced People ,Single Tablet Regimen ,People Living ,Medicaid Had Minimal Impact ,Pharmacy Costs ,Sociodemographic Characteristics Associated ,Tablet Regimens ,Offer Better Persistence ,Lower Costs ,Adherence Status ,Than Multiple Tablet Regimens ,Annual Report ,Adjuvanted Herpes Zoster Subunit Vaccine ,Total Vaccinated Cohort ,Health Estimates ,Global Health Estimates ,Gsk Plc Stock Exchange ,News ,Information ,Press Release ,First ,Presentation ,F ,Rsv ,Ilder ,Adult ,Vaccine ,Pivotal ,Hase ,Wii ,Efficacy ,End ,Safety ,Few ,Data ,Howing Gsk Gb00bn7swp63 ,